深部热疗联合全身化疗治疗晚期卵巢癌的临床效果及对ERCC1、β-catenin及β-tubulin Ⅲ表达的影响

Effects of deep hyperthermia combined with systemic chemotherapy on advanced ovarian cancer and its effect on expression of ERCC1,β-catenin and β-tubulin Ⅲ

目的观察深部热疗联合全身化疗治疗晚期卵巢癌的临床效果及对核苷酸切除修复互补基因1(excision repair cross complementing 1,ERCC1)、β链蛋白(β-catenin)及β微管蛋白Ⅲ(β-tubulinⅢ)表达的影响。方法选取晚期卵巢癌患者80例,按照随机数字表法分为2组,对照组使用紫杉醇联合顺铂化疗,观察组在对照组的基础上进行深部热疗。比较2组临床疗效,静脉血中ERCC1、β-catenin及β-tubulinⅢ水平,生存率和不良反应发生率。结果观察组肿瘤缓解率和腹腔积液控制率均明显高于对照组,ERCC1和β-catenin的mRNA表达和蛋白含量均明显低于对照组,平均生存时间明显长于对照组,2年后生存率明显高于对照组,胃肠道和骨髓抑制发生率明显低于对照组(P<0.05)。结论使用深部热疗联合全身化疗对β-tubulinⅢ无明显影响,但可有效抑制ERCC1、β-catenin基因的表达,提高治疗效果,减轻不良反应,有效延长患者的生存期并提高患者的生存质量。

Objective To study the clinical efficacy of deep hyperthermia combined with systemic chemotherapy in the treatment of advanced ovarian cancer and the effect on excision repair cross complementing 1(ERCC1),β-catenin andβ-tubulinⅢ expression.Methods A total of 80 patients with advanced ovarian cancer treated in our hospital from May 2013 to May 2015 were randomly selected. The control group received paclitaxel combined with cisplatin chemotherapy.The observation group was treated with deep hyperthermia on the basis of the control group.The levels of ERCC1,β-catenin and β-tubulin Ⅲ in the two groups were statistically analyzed,and the survival rate and adverse reactions were analyzed.Results The effective rates of tumor remission and ascites control in the observation group were significantly higher than those in the control group.The mRNA and protein levels of ERCC1 andβ-catenin in the observation group were significantly lower than those in the control group.The mean survival time of the observation group was significantly longer than that of the control group,and the survival rate of the observation group was significantly higher than that of the control group.The incidence of myelosuppression was significantly lower in the observation group than that in the control group(P<0.05).Conclusion The use of deep hyperthermia combined with systemic chemotherapy can effectively inhibit the expression of ERCC1 andβ-catenin genes,improve the therapeutic effect,reduce the incidence of adverse reactions,effectively prolong the survival of patients and improve the quality of life of patients.